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Abstract
Background: Adults with type 1 diabetes (T1D) have decreased bone mineral density (BMD) and increased fracture
risk, yet the etiologies remain elusive. Early detection of derangements in bone biomarkers during adolescence
could lead to timely recognition. In adolescents with T1D, we evaluated the relationships between metabolic
control, BMD, and bone anabolic and turnover markers.
Methods: Cross-sectional study of 57 adolescent subjects with T1D who had HbA1c consistently ≥ 9% (Poor
Control, PC n = 27) or < 9% (Favorable Control, FC n = 30) for two years prior to enrollment. Subjects had T1DM
for at least three years and were without diabetes complications, known celiac disease, or other chronic diseases.
Results: There were no differences between HbA1c groups in BMD, components of the IGF system, or 25-
hydroxyvitamin D status. The prevalence of 25-hydroxyvitamin D abnormalities was similar to that seen in the
general adolescent population. Few patients met the recommended dietary allowance (RDA) for vitamin D or
calcium.
Conclusions: These data provide no evidence of association between degree of metabolic control and BMD in
adolescents with T1D. Adolescents with T1D have a high prevalence of serum 25-hydroxyvitamin D abnormalities.
Longitudinal studies are needed to evaluate the predictive value of vitamin D abnormalities on fracture risk.
Keywords: bone mineral density, intact parathyroid hormone, insulin-like growth factor, type 1 diabetes,
adolescent
Introduction
The effects of improved home blood glucose monitor-
ing, pharmacotherapy, and educational interventions
have led to a longer lifespan for patients with type 1 dia-
betes mellitus (T1D). However, bone health remains a
problem for many with T1D, as adults with T1D have
increased fracture risk and generalized osteoporosis
[1,2], and abnormalities in bone mineral density (BMD)
have been reported in adolescents with T1D. The
underlying mechanisms triggering the changes in BMD
in patients with T1D are not well-known. Reports of the
relationships between metabolic control, BMD, and
bone marker parameters in patients with T1D have
been conflicting [3,4]. Evaluations of bone disease in
adults with T1D are generally complicated by the pre-
sence of other diabetic complications such as nephropa-
thy, muscle insufficiency, or impaired vision that can
affect bone disease. Early detection, prior to other dia-
betes complications, of derangements in bone markers
can provide insight into the pathogenesis of bone dis-
ease in patients with T1D.
Bone health is dependent upon appropriate regulation
of both anabolic and catabolic processes. Insulin-like
growth factor I (IGF-I) is an anabolic regulator of bone
metabolism, and BMD has been positively correlated
with IGF-I levels in both human and animal studies
[5-7]. IGF-I is decreased in patients with T1D, asso-
ciated with the degree of metabolic control [8-10].
Patients with T1D have dysregulation of the growth hor-
mone-IGF-I axis [9-11] and dysregulation of IGF bind-
ing proteins (IGFBP) [9,11], which determine the tissue
availability of IGF-I. Parathyroid hormone has both
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anabolic and catabolic effects on bone. Low, unaltered
or elevated levels of intact parathyroid hormone (iPTH)
have previously been reported in patients with T1D
[12,13]. However, these studies evaluated few patients
and included patients with important confounders such
as diabetic nephropathy that may have led to secondary
hyperparathyroidism. Aberrations in bone markers may
be predictive of osteoporosis and fractures [14]. Bone-
specific alkaline phosphatase, which is a bone formation
marker reflective of osteoblastic activity, is lower in
patients with T1D than controls [15]. In addition, urin-
ary cross linked N-telopeptides of type I collagen
(NTX), bone breakdown markers, are decreased in
patients with T1D [16]. Bone turnover therefore is
decreased in patients with T1D, although the etiologies
are unclear.
Peak bone mass is attained by early adulthood [17],
and therefore interference with this process in adoles-
cence results in life-long complications. Evaluations of
bone disease in adolescents with T1D are limited. This
study was designed to evaluate whether in adolescents
with T1D: 1) poor metabolic control is associated with
reduced BMD; 2) changes in biochemical bone para-
meters such as IGF-I system components, iPTH, bone
turnover markers, and 25-hydroxyvitamin D are asso-
ciated with metabolic control. We also hypothesized
that adolescents with T1D would have a higher preva-
lence of vitamin D deficiency than the healthy adoles-
cent population.
Materials and methods
Participants
Adolescents (ages 13-18 years) with T1D for ≥ 3 years
were recruited from the pediatric clinic in the Eskind
Diabetes Center at Vanderbilt Medical Center. All parti-
cipants were diagnosed with T1D by a pediatric endocri-
nologist. The study was conducted in accordance with
the Declaration of Helsinki and was approved by the
Vanderbilt University Medical Center Institutional
Review Board. Informed consent was obtained from
each participant’s parent/legal guardian, and informed
assent was obtained from each participant prior to
beginning the study. Participants were categorized by
the degree of glucose control. Poor control (PC) was
defined as all (must have a minimum of 3) HbA1c mea-
surements ≥ 9% and favorable control (FC) was defined
as all HbA1c measurements < 9% during the previous 2
years. Exclusion criteria were: presence of microalbumi-
nuria, retinopathy or neuropathy; pre-existing bone dis-
ease, cystic fibrosis or celiac disease, eating disorder,
estro-progesterone or testosterone treatment including
oral contraceptives, smoking, pregnancy, amenorrhea,
polycystic ovarian syndrome as diagnosed by a pediatric
endocrinologist based upon irregular menses as well as
hirsutism and/or biochemical evidence of androgen
excess, obesity [body mass index (BMI) > 95th percen-
tile for age and sex], short stature (< 3rd percentile for
age and sex), or delayed/precocious puberty.
Anthropometric Evaluation
Height and weight were obtained, and body mass index
was calculated based on the following formula: weight
(kg)/height (m)2.
Response variables
1. Bone measurements
The primary dependent variable was BMD measured by
DEXA scan.
Total BMD, lumbar spine (L2-L4) BMD, L2-L4 width,
and femoral neck BMD were determined by dual energy
radiographic absorptiometry (DEXA, GE Healthcare,
Lunar iDEXA, Tube model 40782). Prior to September
2007, DEXA scans were performed using the GE
Healthcare Lunar Model 8743. Lumbar (L2-L4) BMD
and L2-L4 width were used to determine bone mineral
apparent density (BMAD, grams per cubic centimeter),
which was calculated based on the following formula:
BMD (L2-L4) × (4/[pi x width]) [18]. Results were
expressed as z-scores for total body BMD, lumbar BMD,
BMAD, and femoral neck BMD. Z-scores were calcu-
lated using the means and SD reported for age and gen-
der [19]. Serum pregnancy tests were negative on all
females prior to DEXA scan.
2. Laboratory Evaluation
Other dependent variables included components of the
IGF system, bone turnover makers, and serum 25-
hydroxyvitamin D levels. Venous blood samples were
collected after an overnight fast (approximately 10
hours). Participants received their usual evening insulin
glargine dose the night prior or were continued on their
insulin pump at the usual basal rate. For each partici-
pant, serum for IGF-I, IGFBP-3 (insulin-like growth fac-
tor binding protein 3), IGFBP-4, IGFBP-5, iPTH, bone-
specific alkaline phosphatase (BAP), total 25-hydroxyvi-
tamin D, calcium, phosphorus, and creatinine were
obtained. Urine was collected for 24 hours at home
prior to arrival for analysis for cross linked N-telopep-
tides of type I collagen (NTX), creatinine, calcium, and
phosphorus.
3. Diet diary
Subjects were asked to keep a diet diary for 72 hours
prior to the study visit, in order to ascertain information
regarding dietary vitamin D and calcium intake. Each
subject was instructed to record type of food/beverage
and amount consumed in as much detail as possible.
Verbal and written instructions were given to each sub-
ject and his/her parents when consented for the study,
and logsheets were provided for each subject. The
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information from these diet diaries was placed into the
Nutrition Data System for Research (NDSR, University
of Minnesota), and an analysis of calcium and vitamin D
intake per day was obtained.
Exposure variable
The primary independent variable was the average of 3or
more consistent levels of HbA1c in the 2 years prior to
enrollment. Subjects were assigned either to the poor
control (PC) group (HbA1c ≥ 9%) or the favorable con-
trol group (FC) (HbA1c < 9%). Subjects who had HbA1c
values in both categories during the two years prior to
potential study enrollment were excluded. The enroll-
ment plan included that an equal number (± 10%) of sub-
jects would be enrolled in the two metabolic groups. This
targeted enrollment by HBA1c was to ascertain that sub-
jects in poor control were represented in study.
Assay methods
HbA1c was measured by point-of-care immunoassay using
the DCA Vantage Analyzer (Siemens Healthcare Diagnos-
tics, Deerfield, IL, USA). Serum concentration of total IGFI
was measured by radioimmunoassay (RIA) (ALPCO Diag-
nostics, Salem, NH, USA). Inter- and intra-assay coeffi-
cients of variation were 3.4-4.2% and 2.6-4.1%, respectively.
Serum IGFBP-3 was measured by radioimmunoassay (RIA)
using rabbit polyclonal antiserum and human recombinant
IGFBP-3 as standard and tracer [20]. Serum IGFBP-4 was
measured by a specific RIA using recombinant human
IGFBP-4 expressed in Escherichia coli as antigen, tracer
and standard [21]. Antibodies against human IGFBP-4
were developed in guinea pigs as described previously [21].
Inter-and intra-assay variations were less than 8%. There
was no cross-reactivity with other IGFBPs. Serum IGFBP-5
was measured by a specific RIA using recombinant human
IGFBP-5 as antigen, tracer and standard as described [22].
There was no cross-reactivity with other IGFBPs. Inter-and
intra-assay variations were less than 8%. Cross-linked N-
telopeptides in urine were measured by chemiluminescent
immunoassay (ARUP Laboratories, Salt Lake City, UT,
USA). Intact PTH was measured using the Roche Cobas
electrochemiluminescence assay, BAP was measured by the
immunoenzymatic assay Access Ostase, and total 25-
hydroxyvitamin D was measured using Liquid Chromato-
graphy-Tandem Mass Spectrometry (LC-MS/MS) (Mayo
Medical Laboratories, Rochester, MN, USA). The criteria
used to define vitamin D sufficiency, insufficiency, and defi-
ciency were 25-hydroxyvitamin D levels ≥ 30 ng/mL, 15-29
ng/mL, and <15 ng/mL, respectively, as was recently
reported [23].
Statistical methods
Clinical and demographic variables are presented as
number and percent or medians and interquartile
ranges [IQR]. Categorical variables were compared by
HbA1c degree of control group with c2 test and con-
tinuous variables with Wilcoxon rank sum test. Spear-
man correlation coefficients (rho) were used to assess
the correlation of continuous BMD measures, compo-
nents of the IGF system, bone turnover markers, vita-
min D and calcium intake, age, and HbA1c. We
assessed for the adjusted association between BMD
measures, components of the IGF system, bone turn-
over markers, vitamin D and calcium intake and age
with HbA1c as an independent variable with multiple
linear regression analyses. Multivariable linear regres-
sion assumptions of normality of residuals were
checked and were met. Covariates for adjustment were
chosen a priori and included age, gender and race. All
reported p values are unadjusted for multiple tests. All
analyses used a 5% two-sided significance level and
were performed with R version 2.10.10 http://www.r-
project.org. To compare the prevalence of vitamin D
status with published NHANES study report[23], we
calculated the proportion of subjects who were insuffi-
cient and deficient in 25-hydroxyvitamin D by gender
and calculated the 95% confidence interval (CI) for
binomial proportion using the Wilson method. The
Wilson method was used as it works better for calcula-
tion of 95%CI with small samples and extreme prob-
ability (approaching 1 or 0) [24].
Results
Demographic characteristics
The study population included 57 participants, 30 in
the FC group and 27 in the PC group (stable HbA1c
during the 2 years prior to study participation). There
were no significant differences between groups in age,
gender, duration of diabetes, or anthropometrics
(Table 1). As expected based on selection criteria, the
average HbA1c during the two years prior to the
study in the PC group was higher than that in the FC
group.
BMD, bone markers, and components of the IGF system
in FC and PC groups
The FC group had a higher iPTH level [30.5 pg/ml
(21.8, 37.8)] compared with the PC group [19 pg/ml
(15, 31)], p = 0.04. The FC group also had higher
urine n-telopeptides (NTX) than the PC group [238
nM BCE/mM creat (98,366) vs 56 nM BCE/mM creat
(41,311), p = 0.03] and a lower urine Ca/Cr than the
PC group [0.07 (0.05, 0.15) vs 0.14 (0.09, 0.21), p =
0.02], consistent with higher iPTH levels (Table 2).
There were no differences between groups in mea-
surements of BMD, IGFI or IGFBPs, BAP, serum cal-
cium, serum creatinine, eGFR, or 25-hydroxyvitamin
D levels.
Simmons et al. International Journal of Pediatric Endocrinology 2011, 2011:13
http://www.ijpeonline.com/content/2011/1/13
Page 3 of 8
Relationship between metabolic control and BMD, bone
markers, IGF system components and vitamin D/calcium
intake
Univariate analyses (Table 3) demonstrated a positive
correlation between HbA1c and % body fat (rho = 0.30,
p = 0.02) and urine Ca/Cr (rho = 0.27, p = 0.047) and
negative correlations between HbA1c and NTX (rho =
-0.36, p = 0.01), intact PTH (rho = -0.28, p = 0.04), and
serum creatinine (rho =-0.27, p = 0.04). There were no
other significant correlations between HbA1c and any of
the other study variables. After controlling for age, sex,
and race, there was a positive association between
HbA1c and serum phosphorus and a negative associa-
tion between HbA1c and serum creatinine that were
statistically significant. There were no associations
between HbA1c and BMD, bone turnover markers,
components of the IGF system, serum 25-hydroxyvita-
min D, serum calcium, or dietary intake of calcium and
vitamin D.
Dietary Intake of vitamin D and calcium
Subjects with T1D who have favorable metabolic control
report consuming a similar amount of vitamin D and
calcium as those who have poor metabolic control
(Table 2). Only 12% (3/25) of the total subgroup with
intake data reported consuming the recommended daily
allowance (RDA) of vitamin D (400 IU/day at the time
of the study), and 16% (4/25) of the total subgroup
reported consuming the RDA for calcium (1300 mg/
day), with no differences between groups (18% vs 12%, p
= 0.74). When evaluated with the Institute of Medicine’s
2011 RDA of 600 IU vitamin D/day [25], only 1 subject
reported consuming this amount.
Table 1 Characteristics of subjects by metabolic control,
results shown as median and [IQR] interquartile range.
Favorable Control
(n = 30)
Poor Control
(n = 27)
p value*
HbA1C (%) 7.7 [7.3, 7.9] 10.3 [9.9, 11.4] **
Age (yrs) 15.2 [14.3, 16.1] 16.4 (15.1, 17.8) 0.05
Gender (% female) 37% 59% 0.42
Race (% Caucasian) 87% [26/30] 81%[21/26] 0.55
Duration DM (yrs) 6.5 [4.8,8.0] 6.5[5.5,9.5] 0.40
Height (cm) 169.8 [ 158.6,178.1] 163.2 [16.03,165.7] 0.22
Weight (kg) 68.5 [55.4,74.0] 67.5 [ 59.0,77.5] 0.91
BMI (kg/m2) 22.8 [20.4,27.5] 25.0 [21.4,27.9] 0.35
*Wilcoxon rank sum test for continuous variables or c2 test for categorical
variables.
** Groups were defined based on HbA1c
Table 2 Clinical and biochemical features of subjects with T1D
n FC (n = 30) PC (n = 27) p value†
Lumbar spine BMD* 56 0.01 (-1.14, 1.07) -0.46 (-0.82, 0.37) 0.58
Volumetric lumbar spine (BMAD)* 56 0.05 (-0.63, 0.69) -0.14 (-0.48, 0.57) 0.83
Femoral neck BMD* 56 0.12 (-1.23, 0.98) -0.48 (-1.19, 1.39) 0.66
Total body BMD* 56 0.46 (-1.27, 1.35) -0.03 (-1.1, 0.72) 0.66
% body fat 56 28.7 (16.7, 35.3) 33.7 (20.2, 40) 0.22
IGF-1 (ng/mL) 56 564 (430, 644) 488 (402, 603) 0.29
IGF BP-3 (μg/L) 54 2883 (2448, 3060) 2901 (2676, 3436) 0.36
IGF BP-4 (μg/L) 54 398.5 (334.8, 439.2) 415.5 ± 57.9 0.17
IGF BP-5 (μg/L) 54 346.0 (300.8, 384.2) 316.5 (273.2, 447.8) 0.55
NTX (nM BCE/mM creat) 54 238 (98, 366) 56 (41, 311) 0.03
Bone-Specific Alkaline Phosphatase (ug/L) 53 34 (23, 63) 19 (14.5, 49.5) 0.09
Intact PTH (rg/mL) 53 30.5 (21.8, 37.8) 19 (15, 31) 0.04
Serum 25-hydroxyvitamin D (ng/mL) 52 31 (21, 37) 32 (24, 38.5) 0.76
Serum Calcium (mg/dL) 56 9.4 (9.3, 9.7) 9.4 (9.2, 9.6) 0.99
Serum Phosphorus (mg/dL) 56 4.4 (4.1, 5.0) 4.8 (4.3, 5.2) 0.21
Serum creatinine (mg/dL) 56 0.75 (0.63, 0.8) 0.7 (0.6, 0.8) 0.22
eGFR estimation (ml/min) 56 137.5 (122.7, 149.8) 141.8 (118.2, 166.4) 0.72
uCa/uCr 54 0.07[0.05, 0.15] 0.14[0.09,0.21] 0.02
uPhos/uCr 54 0.80[0.64, 0.92] 0.90[0.72, 1.0] 0.22
Average vitamin D intake/day (IU) 25 173 (128, 246) 168 (122, 246) 1
Average calcium intake/day (mg) 25 872 (651, 1136) 686 (574, 927) 0.46
Items in bold p < 0.05.
† Wilcoxon rank sum test for comparison of continuous variables
* z-scores
Abbreviations: FC: Favorable Control, PC: Poor Control, BMD: bone mineral density, BMAD: bone mineral apparent density, eGFR (estimated glomerular filtration
rate)
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Hydroxyvitamin D statusThere were no differences
between groups in serum 25-hydroxyvitamin D levels
(Table 2), with 14% of the FC group deficient (25-hydroxy-
vitamin D levels < 15 ng/ml) and 31% insufficient (25-
hydroxyvitamin D levels 15-29 ng/ml) and 13% of the PC
group deficient and 35% insufficient in serum 25-hydroxy-
vitamin D, p = 0.96. Together, there were no differences
between subjects with T1D and the normal adolescent
population [23] in the prevalence of 25-hydroxyvitamin D
deficiency, as 11% (95%CI: 2.9%, 31.4%) of girls and 0%
(95%CI: 0, 13.3%) of boys with T1D were deficient in 25-
hydroxyvitamin D, compared with 5% and 3% of the nor-
mal adolescent population, respectively. Thirty-two per-
cent of girls (95%CI: 15.4%, 54.0%) and 40% (95%CI:
23.4%, 59.2%) of boys were insufficient in 25-hydroxyvita-
min D, compared with 57% and 63%, respectively, of the
general adolescent population. When using the 2011 Insti-
tute of Medicine Report’s definition of vitamin D inade-
quacy [25], 21% of the FC group and 17% of the PC group
had 25-hydroxyvitamin D levels <20 ng/ml, p = 0.76.
Discussion
This study addresses whether metabolic control has an
effect on bone health in patients with T1D who have
not yet achieved peak bone mass. Adolescents with T1D
in consistently poor metabolic control appear to have
lower iPTH levels than a group of adolescents with T1D
in favorable metabolic control, although this association
was attenuated when adjusted for age, gender and race.
After adjustment, urine calcium is associated with meta-
bolic control, consistent with lower iPTH levels. We
also explored the prevalence of 25-hydroxyvitamin D
abnormalities in adolescents with T1D, as vitamin D
abnormalities have been increasingly recognized as a sig-
nificant health problem both for healthy patients and
those with chronic illnesses [26]. Adolescents with T1D
have significant 25-hydroxyvitamin D abnormalities, but
these abnormalities are not more prevalent than in the
general adolescent population.
Poor bone health is a significant problem for many
adults with T1D, as is demonstrated by a two-fold
increase in fracture risk in the lumbar spine, femoral
neck, and distal radius [1]. Women with T1D have
more than a 10-fold increase in risk of hip fractures
compared with age-matched controls [2]. Almost 20% of
patients with T1D ages 20-56 years meet criteria for
osteoporosis [27], which is a debilitating illness that
impairs functionality and quality of life [28]. However,
Table 3 Association between HbA1c and bone mineral density measurements, components of the IGF system, bone
turnover markers, and dietary intake of calcium and vitamin D
Spearman correlation coefficient p value* Adjusted p value **
Age 0.24 0.08
Lumbar Spine BMD † -0.12 0.37 0.63
Volumetric Lumbar Spine † (BMAD) -0.041 0.76 0.85
Femoral neck BMD † -0.056 0.68 0.24
Total body BMD † -0.086 0.53 0.87
% Body fat 0.30 0.02 0.66
IGF-I (ng/ml) -0.15 0.27 0.92
IGFBP3 (μg/L) 0.13 0.37 0.33
IGFBP4 (μg/L) 0.23 0.10 0.1
IGFBP5 (μg/L) -0.09 0.52 0.65
NTX (nM BCE/mM creat) -0.36 0.01 0.73
Bone-specific alkaline phosphatase (μg/L) -0.26 0.06 0.81
Intact PTH (rg/ml) -0.28 0.04 0.2
Serum 25-hydroxyvitamin D (ng/ml) -0.047 0.74 0.89
Serum Calcium (ml/dL) 0.15 0.28 0.19
Serum Phosphorus (mg/dL) 0.2 0.14 0.01
Serum creatinine (mg/dL) -0.27 0.04 0.007
UCa/uCr 0.27 0.047 0.05
uPhos/uCr 0.22 0.1 0.37
Average vitamin D intake/day (IU) -0.09 0.67 0.55
Average calcium intake/day (mg) -0.13 0.55 0.42
Items in bold p < 0.05.
*Spearman correlation coefficient p value; ** p value adjusted for age, race, and gender; † z-scores
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the etiologies of decreased BMD in adults with T1D
have been unclear [29,30]. The mechanisms of osteo-
porosis associated with T1D differ from the develop-
ment of osteoporosis associated with aging [31], and
several potential mechanisms have been proposed,
including effects of advanced glycation end products in
bone collagen [32], increased urinary excretion of cal-
cium, phosphate and magnesium [33], inflammatory
cytokines [34], low levels of iPTH [12], diabetic micro-
angiopathy with reduced blood flow to bone [35],
decreased bone resorption [16], decreased bone forma-
tion [36], and vitamin D deficiency [37]. We sought to
evaluate whether poor metabolic control during adoles-
cence is associated with abnormal bone health.
Previous studies investigating the role of metabolic
control and BMD in patients with T1D have been lim-
ited by older BMD measurement methods which may
be inaccurate, limited knowledge in the consistency of
patients’ actual metabolic control (many studies use
only a single HbA1c measurement as the index of meta-
bolic control), and confounding factors affecting BMD
such as the use of oral contraceptives. In this study, we
controlled confounding factors and found no correla-
tions between metabolic control and BMD, similar to
others [3,38,39], but differing from some [4]. Although
subjects had stable diabetes control for two years prior
to the study, two years of poor diabetes control may not
be long enough to lead to changes in BMD demon-
strated by DEXA scans in adolescents.
The role of IGF-I as a critical anabolic regulator of
BMD is clearly demonstrated in animal studies in which
genetic manipulation of the IGF system led to osteope-
nia [7]. In humans, cross-sectional and cohort studies in
various populations, including subjects from the Fra-
mingham Heart Study, have demonstrated a strong cor-
relation between serum levels of IGF-I and BMD [6,40].
Dysregulation of the IGF-I/IGFBP system has been
reported in patients with T1D [9-12,32]. We found no
associations between metabolic control and components
of the IGFI system, although other studies have reported
that IGF-I levels correlate with metabolic control [11].
As we did not have a control group of healthy subjects,
IGFI levels may be too low within a population of T1D
patients to detect significant differences.
Only 35% of healthy non-Hispanic white adolescents
are sufficient in 25-hydroxyvitamin D [23], which plays
an important role in the maintenance of bone health.
Similar to recent studies, we found a significant preva-
lence of 25-hydroxyvitamin D abnormalities in adoles-
cents with T1D [37,41], but we did not find a difference
in 25-hydroxyvitamin D status between adolescents with
T1D and the normal adolescent population [23]. How-
ever, the proportions of vitamin D sufficiency status by
gender were limited by small numbers which resulted in
proportions with wide confidence intervals. There is not
enough evidence to support that metabolic control plays
a role in vitamin D status, and other risk factors need to
be evaluated.
Only one subject reported consuming the current
RDA for vitamin D, with 16% consuming the RDA for
calcium. This is not different from the healthy adoles-
cent population, as previous data from NHANES III
(1988-1994) demonstrated that only 53-63% of all US
children consume at least 200 IU of vitamin D per day
from diet and/or supplementation. (200 IU was reported
in this paper because it was considered Adequate Intake
for vitamin D at that time) [42]. This is of particular
concern for adolescent patients with T1D, as vitamin D
and calcium intake are modifiable factors that have a
significant impact on BMD.
Our study had several limitations. We stratified by
design the subjects into poor and favorable metabolic
control groups, and we could have missed relationships
between HbA1c and study variables due to a lack of a
full continuous spectrum of HbA1c values. We did not
have a control group of non-diabetic patients. Also, we
did not obtain information regarding exercise and speci-
fics regarding pubertal development, which clearly have
an effect on BMD and bone turnover. However, we
attempted to address this issue by excluding patients
with obesity as well as known pubertal delay, amenor-
rhea, or polycystic ovarian syndrome.
In summary, metabolic control is not associated with
BMD as evaluated by DEXA in this adolescent popula-
tion with T1D, and bone anabolic and turnover markers
are not affected by metabolic control, once age, gender,
and race are taken into account. Adolescents with T1D
are frequently vitamin D insufficient, which is likely also
playing an important role in bone metabolism.
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